By Rob Goszkowski, Assistant Editor Dr. Bicuspid September 1, 2011 — As it rolls out clinical recommendations, the ADA is on a mission to guide general dentists to a decision-making process that combines the doctor’s experience and the patient’s preference with…
Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy. The Company has retained PRA International as the Clinical Research Organization (CRO) for clinical trials management services related…
View Print Edition
View Digital Edition
View Special Edition